Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

Phase 3

Completed

Conditions: Nasal Polyps
Chronic Rhinosinusitis

Interventions: Drug: Omalizumab
Drug: Placebo

First Posted Date: 2018-03-27

Last Posted Date: 2022-04-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 249

Registration Number: NCT03478930

Locations: 🇺🇸
Jonathan Corren MD, Inc., Los Angeles, California, United States
🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸
Vitae Research Center, Miami, Florida, United States

and more 76 locations

A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease

Phase 1

Terminated

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Etrolizumab

First Posted Date: 2018-03-27

Last Posted Date: 2024-12-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT03478956

Locations: 🇵🇱
Centrum Zdrowia MDM, Warszawa, Poland
🇪🇸
Hospital Niño Jesus; Servicio de Pediatria - Gastrenterologia y Nutricion, Madrid, Spain
🇬🇧
Royal Manchester Childrens Hospital, Manchester, United Kingdom

and more 2 locations

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase 1

Active, not recruiting

Conditions: B-Cell Lymphoma
Non-Hodgkin Lymphoma

Interventions: Drug: Glofitamab
Drug: Obinutuzumab (G)
Drug: Rituximab (R)
Drug: Tocilizumab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Polatuzumab vedotin
Drug: Prednisone

First Posted Date: 2018-03-16

Last Posted Date: 2024-10-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 172

Registration Number: NCT03467373

Locations: 🇩🇰
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
🇺🇸
University of Alabama Medical Center, Birmingham, Alabama, United States
🇺🇸
Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States

and more 21 locations

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Phase 3

Active, not recruiting

Conditions: Non-Small-Cell Lung

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Drug: Placebo Comparator
Drug: Nab-paclitaxel
Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2018-03-07

Last Posted Date: 2024-11-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 453

Registration Number: NCT03456063

Locations: 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Arizona Oncology, Tucson, Arizona, United States
🇺🇸
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California, United States

and more 124 locations

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Alectnib
Drug: Cisplatin
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2018-03-07

Last Posted Date: 2024-08-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 257

Registration Number: NCT03456076

Locations: 🇷🇺
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺
Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺
GUZ Regional clinical hospital # 1, Krasnodar, Russian Federation

and more 136 locations

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Early Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: RXDX-106

First Posted Date: 2018-03-05

Last Posted Date: 2019-04-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1

Registration Number: NCT03454243

Locations: 🇺🇸
START, San Antonio, Texas, United States

A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 3

Terminated

Conditions: Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions: Drug: Atezolizumab
Drug: Placebo

First Posted Date: 2018-03-02

Last Posted Date: 2024-10-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 406

Registration Number: NCT03452137

Locations: 🇺🇸
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States
🇺🇸
Cleveland Clinic; Taussig Cancer Institute, Cleveland, Ohio, United States
🇧🇷
Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil

and more 132 locations

A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus

Not Applicable

Completed

Conditions: Diabetes Mellitus

Interventions: Device: Eversense XL CGM System
Device: Usual SMBG or FGM device used by participants

First Posted Date: 2018-02-26

Last Posted Date: 2021-09-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 239

Registration Number: NCT03445065

Locations: 🇫🇷
CHU Amiens Picardie, Amiens, France
🇫🇷
Hopital Hotel Dieu - Creusot, Le Creusot, France
🇫🇷
CHRU de Lille, Lille, France

and more 17 locations

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: Gantenerumab

First Posted Date: 2018-02-23

Last Posted Date: 2024-01-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 975

Registration Number: NCT03443973

Locations: 🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
Texas Neurology PA, Dallas, Texas, United States

and more 152 locations

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Gantenerumab
Drug: Placebo

First Posted Date: 2018-02-23

Last Posted Date: 2024-01-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1053

Registration Number: NCT03444870

Locations: 🇺🇸
Bradenton Research Center, Bradenton, Florida, United States
🇺🇸
Neurology Consultants of Dallas; Research Department, Dallas, Texas, United States
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 169 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy